To evaluate the effectiveness and cost of low osmolarity, nonionic contrast agents for cardiac angiography, 443 patients were randomized to receive either iopamidol or diatrizoate. All adverse events that occurred within 24 h of the procedure were recorded prospectively by study personnel and classified according to previously determined criteria. Major events were defined as life threatening or requiring a procedure to treat, or both. Costs of the catheterization procedure, pharmacy, hospital laboratory and treatment of adverse events were determined on the basis of actual resource use.
A total of 20 patients (8.5%) had major and 143 (61 %) had minor adverse events with diatrizoate use; 10 patients Cardiac catheterization is a well established procedure to document the presence and severity of cardiac disease. In 1986 cardiac angiography was performed on 592.000 patients in the United States (1). Although standard contrast agents used in angiography are relatively well tolerated. they have a number of undesirable effects, particularly on the cardiovascular system and kidney (2) . Intracoronary contrast injection may cause a variety of arrhythmias including ventricular fibrillation, sinus bradycardia and atrioventricular block. The negative inotropic effects of contrast agents may induce hypotension or pulmonary edema. Renal failure induced by contrast agents remains a major concern, total events). Most adverse events were treated fairly easily and inexpensively. The median overall cost was $186 higher for patients after iopamidol use compared with diatrizoate (p < 0.0001), but all costs except the cost of the contrast agent were not significantly different between the two groups. Thus, patients who received iopamidol for cardiac angiography had a significantly lower rate of adverse events than those who received diatrizoate, but this difference was achieved at a considerably high overall cost.
() Am Coli Cardiol1990; 16:871-7) particularly in patients with preexisting renal insufficiency (3, 4) .
Newly developed radiographic contrast agents that are low in osmolarity appear to have a relatively low incidence of adverse events during coronary angiography (5) (6) (7) (8) . In small, randomized studies (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) intracoronary injection of these newer agents has been associated with less bradycardia and hypotension than has injection of conventional contrast agents. However. it is not certain that the rate of serious clinical complications such as pulmonary edema, ventricular fibrillation and renal failure is lower with the newer contrast media. Furthermore, the cost of low osmolarity contrast agents is 10 to 20 times that of conventional agents (8) and adoption of the newer agents for routine cardiac angiography could add more than $100 million annually to the nation's health care costs.
Adoption of new and expensive low osmolarity contrast agents might be justified if the rate of serious adverse events were considerably lower (7) . It is possible that a reduction in the cost of treating adverse events might offset the added expense of the contrast agents. However, there are few data available regarding this question. The purpose of this study was to evaluate the relative advantages and costs of a Table 1 . Classification of Adverse Events were defined as those neither requiring major treatment nor posing a risk to life. Data concerning any adverse events were reviewed by a panel of at least three cardiologists masked to treatment assignment. All adverse events were graded as definitely related, possibly related or not related to cardiac catheterization; adverse events were also graded as definitely related, possibly related or not related to administration of a contrast agent.
The research assistant also collected data regarding hospital resource consumption in the 24 h after catheterization. The number and type of laboratory tests, medications and length of stay in the hospital and intensive care units were recorded on standard study forms.
Patient evaluation. All patients were requested to complete a self-administered questionnaire after the catheterization procedure. They were asked, "How happy, satisfied or pleased have you been with your care during your cardiac catheterization test'?" The six possible responses ranged from "Extremely happy. could not have been more satisfied or pleased" to "Very dissatisfied, unhappy most of the time." They were also asked, "Did you have any discomfort from feeling hot and flushed during the test?" and "Were you sick to your stomach during the test'?" Four possible responses ranged from "No. none" to "Yes. severely."
Cost analysis. The cost analysis was based on the concept of attributing certain resources consumed to each case, nonionic, low osmolarity contrast agent (iopamidol) for cardiac angiography.
Methods
Study design. The design of this study has been reported previously (4) . In brief, all patients undergoing elective cardiac catheterization at the Veterans Affairs Medical Center, Durham were considered eligible for the study. The study was approved by the institutional review boards of Duke University Medical Center and the Veterans Affairs Medical Center, Durham.
On the basis of the initial evaluation, patients were stratified into groups at high and low risk for adverse events induced by contrast agents. The high risk group consisted of patients with either diabetes mellitus (treated with insulin or an oral hypoglycemic agent) or renal insufficiency (serum creatinine levels 2: 133 ,umol/liter) or congestive heart failure (rales, 53 gallop or radiographic evidence of vascular redistribution or pulmonary edema); the remaining patients formed the low risk group. Patients in the low and high risk groups were randomized separately with use of a sealed envelope system. The patients were masked as to the type of contrast agent received but the laboratory staff was not. End point data were evaluated by persons masked to treatment assignment.
Angiographic procedure. Patients without congestive heart failure were given intravenous fluids overnight before angiography (usually I liter of 5% dextrose in 0.45% saline solution) as a routine clinical precaution against nephrotoxicity. Intravenous fluids were continued at a rate of 125 ml/h for 4 h after the procedure. After premedication with 25 to 50 mg of diphenhydramine intravenously, catheterization was performed with the Judkins technique. Left ventriculography and then coronary angiography were performed with either iopamidol (lsovue 370) or diatrizoate (Renografin-76 or Hypaque) according to randomization assignment. Administration of heparin during the procedure was not standardized by protocol but 64% of patients randomized to receive iopamidol and 66% of patients randomized to receive diatrizoate were given heparin (3,000 to 5,000 U) after arterial access was obtained. Procedural data were recorded by the catheterization technician and cardiovascular fellow on standardized forms for computer entry. Blood pressure and electrocardiographic (ECG) rhythm strip were recorded during all injections for later measurement of changes in blood pressure and heart rate by an observer masked to the type of contrast agent administered.
Adverse events (Table 1) . A research assistant followed up all patients for 24 h to determine the subsequent occurrence of adverse events, which were classified according to a schema established before the study. Major events were defined as those that were life threatening, required major intervention or increased the intensity of care. Minor events *N umber of events exceeds the number of patients with events because more than one event per patient occurred in some cases.
*N umber of events exceeds the number of patients with events because more than one event per patient occurred in some cases. assigning cost values to each resource and then summing the individual costs to estimate a total cost. Costs in each category were calculated with only the variable cost component, that is, only the supply and personnel costs were included and fixed costs (such as equipment) and hospital overhead were excluded. Unit cost data were obtained from administrative personnel at Duke University Medical Center. Supply costs were determined directly from invoices and personnel costs were assigned on the basis of time required to perform a given task multiplied by the wage and fringe benefit rate. Catheterization costs were defined as those incurred in the catheterization laboratory including supplies. medications and technician time. Hospital laboratory costs were those incurred for arterial blood gas determinations. differential blood cell counts. blood chemistry panels, coagulation studies. ECG, chest roentgenograms. urinalysis, lipid levels. cardiac enzyme levels and other miscellaneous tests. Pharmacy costs included medications the patient received on the day of catheterization and the day after catheterization. Procedure costs were those incurred because of adverse events including the cost of treatment and any additional hospital days needed.
Statistics. Statistical analyses of discrete valued variables were performed with use of the chi-square or Fisher's exact test. Continuous valued variables were analyzed with the Wilcoxon rank sum test.
Results
Study patients. Four hundred eighty-three patients underwent left heart catheterization with angiography during the study period. Eleven patients were catheterized on an emergency basis for acute myocardial infarction and were not randomized, 26 patients were excluded for logistic reasons and 3 patients refused randomization. The remaining 443 patients were randomized. 208 to receive iopamidol and 235 to receive diatrizoate. The median age of the population was 61 years and all but three patients were men. One hundred sixty patients were in the predefined high risk group, 90 because of diabetes, 66 because of congestive heart failure and 42 because of renal insufficiency (34 patients met more than one criterion for high risk).
Angiographic imaging efficacy. 10j)amidol and diatrizoate were equivalent in imaging effectiveness. The visualization of the coronary arteries was rated by the cardiovascular fellows as adequate in 100% of patients given diatrizoate and in 99% of patients given iopamidol. The quality of the ventriculogram was adequate in 91% of patients given diatrizoate and in 94% of patients given iopamidol. The time spent in the catheterization laboratory was slightly less among patients given iopamidol than among those given diatrizoate (median 70 versus 75 min, p = 0.34).
Adverse events (Tables 2 and 3 ). The immediate effects iopamidol. However, the change in left ventricular enddiastolic pressure after diatrizoate and iopamidol was comparable (median change 1 mm Hg in both groups. p = 0.35). Table 2) . Major adverse events were noted in 20 patients (8.5%) given diatrizoate and in 10 patients (4.8%) given iopamidol (p = 0.12), whereas minor events (unassociated with major events) were noted in 143 patients (61%) given diatrizoate and in 53 patients (25%) given iopamidol. The incidence of all adverse events was significantly reduced in the iopamidol group (p < 0.0001). The vast majority of these adverse events consisted of either transient bradycardia that responded to cough or angina that responded to sublingual nitroglycerin (Table 2 ).
Adverse events were less frequent during the 24 h observation period after administration of iopamidol than afier diatrizoate (
In the case of iopamidol, fewer adverse events were judged to be definitely or possibly related to administration of the contrast agent ( Table 3) . Fourteen patients (6%) had major and 133 (57%) had minor adverse events attributable to diatrizoate and 4 (2%) had major and 39 (19%) had minor adverse events attributable to iopamidol. The risk reduction among patients given iopamidol was comparable for both major and minor adverse events. Again. most adverse events related to administration of the contrast agent consisted of transient bradycardia responsive to cough or angina responsive to nitroglycerin.
Patient evaluation (Table 4 ). The subjective evaluation by the patient of the catheterization procedure was considerably different between those who received iopamidol and those who received diatrizoate. Overall satisfaction with the cardiac catheterization procedure was slightly higher among patients given iopamidol, although this was not statistically significant. The flushing sensation associated with left ventriculography was blunted significantly (p < 0.001) among patients given iopamidol. In addition, nausea associated with the contrast injection was significantly less among patients
, which paralleled the difference in contrast agent-related vomiting between patients receiving diatrizoate (6%) and iopamidol (2%) ( Table 3 ). Cost analysis (Table 5) . Despite the marked reduction in adverse events, the overall cost was $186 higher among patients randomized to receive iopamidol (p < 0.0001). The cost of treating adverse events was somewhat lower in the patients who received iopamidol, but the amount saved was not sufficient to offset the higher cost of the contrast agent. The hospital length of stay after cardiac catheterization was similar in the patients given diatrizoate and those given iopamidol (median 2 days each). The incidence of transfer to intensive care units was similar in both groups (6% for diatrizoate versus 4% for iopamidol) and the length of stay in intensive care was comparable (median 0 days, mean 0.4 in each group).
Outcome in high risk group. Presence of diabetes, congestive heart failure or renal insufficiency defined the high risk group in this study. To determine whether this definition was useful in separating patients into groups with different rates of adverse events, data from all high risk patients were combined, as were the data from all low risk patients, regardless of randomization assignment. The 160 patients in the predefined high risk group had an incidence of major adverse events related to use of a contrast agent that was twice as high as the incidence among the 283 patients in the low risk group (6% versus 3%, p = 0.09). The median overall cost was $70 greater in the high risk group than in the low risk group (p = 0.0007).
Discussion
This randomized controlled trial demonstrates that adverse events during and after cardiac angiography can be reduced 50% to 70% by substitution of iopamidol for diatriwate. However. most adverse events were fairly minor and could be treated easily and inexpensively. Despite the marked reduction in adverse events, the overall median cost (including the catheterization procedure, pharmacy, labora-tory tests and costs of treating adverse events) was $186 higher among patients given iopamidol, almost exclusively because of the higher cost of the contrast agent.
Clinical effectiveness. Previous small, randomized studies of the contrast agents iopamidol (9-12), iohexol (13) (14) (15) (16) (17) and ioxaglate (18) (19) (20) during cardiac angiography have demonstrated that these newer contrast agents reduce the incidence of hypotension and bradycardia during contrast injection. None of these studies has been of sufficient size to examine the effects of these newer contrast agents on more serious complications. A retrospective analysis of 3,313 patients who underwent cardiac angiography at Duke University Medical Center (21) suggested that the risk of adverse events related to use of contrast agents could be reduced by two thirds among patients given iopamidol in comparison with patients given diatrizoate. That study, although it was not randomized and had a historical control group, yielded an estimate of risk reduction remarkably similar to that found in the present randomized trial.
The adverse events most strikingly reduced by iopamidol were bradycardia, angina, nausea and vomiting (Table 3) . Bradycardia during conventional contrast injection may be due to the calcium chelating properties of the ionized material. Most previous investigators (12, 13, 15, 16) demonstrated that the decrease in heart rate during injections could be blunted by nonionic contrast material. Angina during contrast injection may be due to the coronary vasodilation and reactive hyperemia induced by high osmolarity contrast material. The relatively low osmolarity of iopamidol in comparison with diatrizoate may be responsible for the reduction in angina seen in this study. Vomiting during contrast injection appears to represent a direct effect of the contrast agent on the medullary chemoreceptor zone. Although the precise mechanism for the effect is not known, nausea and vomiting were clearly reduced in the iopamidol group.
Although iopamidol reduced the incidence of adverse events in this study, our results do not imply that use of the agent would reduce the incidence of more serious events such as renal failure, myocardial infarction, stroke or death. In large series of patients undergoing cardiac angiography with conventional ionic contrast agents, there has been a reported incidence of such events of roughly 0.1%. Not surprisingly, we did not observe any of these relatively rare events in this study of 443 patients. More than 50,000 patients would have to be studied to deduce a difference between event rates of 0.1 % and 0.2% with good statistical power (a ;::::80% chance of detecting a difference if one existed) and >5,000 patients would have to be studied to detect a difference between event rates of 1% and 2%. Thus, only very large studies would be able to determine whether the newer contrast agents would reduce the incidence of these most serious complications after cardiac angiography.
The effects of iopamidol on renal function and thromboembolic events appear to differ from its effect on other adverse events.
Previous data published from this study showed similar changes in serum creatinine levels after angiography with either iopamidol or diatrizoate (4) and renal failure requiring dialysis has been reported among patients given iopamidol (22) . Myocardial infarction and stroke after angiography are usually due to either mechanical trauma or thromboembolism. Mechanical complications of catheterization should not be affected by the type of contrast agent used. In a previous observational study (21) from our institution, there were five cases of coronary embolism among 3,313 patients given iopamidol (0.15%, confidence interval 0.05% to 0.35%) and two cases among 2,650 patients given diatrizoate (0.09%, confidence interval 0.009% to 0.27%). Because ionic contrast agents also have greater anticoagulant properties in vitro than nonionic agents (23) , nonionic contrast agents may actually increase the risk of thromboembolism during cardiac catheterization. Additional large studies will be needed to establish statistically reliable conclusions regarding the relative effects of ionic and nonionic contrast agents on thromboembolism.
Effects on cost. The newer contrast agents are much more costly than conventional contrast agents. In this study the median cost of contrast agent to the hospital was $207 per patient for iopamidal versus $20 for diatrizoate. We found no evidence that the higher cost of iopamidol was offset by a reduction in the cost of treating adverse events because the adverse events we observed were generally treated simply and inexpensively. If these results can be extrapolated to a national level. routine use of newer contrast agents for coronary angiography would add more than $100 million in costs annually and adoption of newer contrast agents for all angiographic procedures could add more than $1 billion in costs annually.
Are the newer contrast agents worth the substantially higher cost? The present study cannot answer this key question. We observed a striking reduction in minor adverse events but only a statistically insignificant trend toward reduction in major events. No randomized study of the newer contrast agents for coronary angiography has documented a reduction in death, myocardial infarction, stroke or renal failure. As discussed earlier, we do not believe a reduction in minor adverse events can be extrapolated to imply that newer contrast agents would reduce the catastrophic complications of coronary angiography. Nevertheless, if it is assumed that low osmolarity contrast agents could reduce the mortality rate for angiography from 0.1 %to 0.05%, the cost-effectiveness of routine use of iopamidol for coronary angiography can be calculated to be $374,000 per death prevented. Thus, even if it is assumed that the newer contrast agents would reduce the mortality rate after coronary angiography (and no solid data are yet available to support this hypothesis), the cost per death prevented appears to be very high.
The cost-effectiveness of low osmolarity contrast aRents for coronary anRiography could he enhanced in one of two ways: I) High risk patients have more to gain from use of low osmolarity contrast agents and the greater expense in such patients can be more easily justified. Formal costeffectiveness analyses of the newer contrast agents for general angiography suggest that these agents are much more cost-effective when applied to high risk patients (7, 24) .
2) The cost-effectiveness of the newer agents would be increased substantially if the price were lowered. Despite the introduction of several different forms of nonionic or low osmolarity contrast agents by different manufacturers, the price has remained quite high and price competition has yet to emerge among these agents.
Limitations of study. This study was conducted in a Veterans Affairs Medical Center, which does not charge patients for services. We determined costs by counting resources consumed and identifying only the costs that would be expected to vary according to the number of patients treated. For example, the cost of the catheterization procedure included disposable supplies and personnel time but specifically excluded hospital overhead and fixed costs such as those for radiographic equipment. Thus. the dollar figures represent the marginal economic cost to the hospital of replacing diatrizoate with iopamidoI. not necessarily the cost to patients or third party payers.
This study has a numher of limitations: I) The patients were drawn from a Veterans Affairs Medical Center population, which consisted almost exclusively of men and probably differed from the population in other medical centers. 2) We did not study the effect of iopamidol or diatrizoate during coronary angioplasty and cannot comment directly on the relative effectiveness of these agents in that setting. To the extent that adverse events during angioplasty are due to the contrast agent rather than to the mechanical effects of the procedure, it would be reasonable to extrapolate our findings to patients undergoing coronary angioplasty.
3) The cost analysis did not determine the patient's willingness to pay for any changes in discomfort according to the type of contrast agent administered. 4) Finally, the potential costs associated with low probability events or malpractice litigation could not be assessed.
Clinical implications. Routine use of iopamidol for cardiac angiography would reduce adverse events and improve patient comfort but add $186 to the cost for a typical patient.
We were unable to demonstrate that the higher cost of iopamidol would be balanced by a decrease in the costs of treating adverse events. Although additional data from larger studies would define the efficacy of iopamidol more completely, no amount of data will eliminate the need to include value judgments in any assessment of whether the newer. more expensive contrast agents are worth the added cost.
